TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05739981: Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Sponsor: Imunon · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$1,060,290

Rescue Site Savings

+$706,860

Unlock Full NCT05739981 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05739981 Rescue Dossier →